Truist lowered the firm’s price target on IGM Biosciences (IGMS) to $1 from $2 and keeps a Hold rating on the shares. The firm has updated tis model to reflect Q1 financial results and the company’s forward outlook, adding that it is waiting for any potential announcement regarding a strategic pivot from the company, the analyst tells investors in a research note.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IGMS: